DOI: https://doi.org/10.22263/2312-4156.2024.4.70
A.I. Masyukevich
Anticytokine therapy for experimental acute destructive pancreatitis
Grodno State Medical University, Grodno, Republic of Belarus
Vestnik VGMU. 2024;23(4):70-78.
Abstract.
Objectives. To study the effect of tocilizumab on the severity of the development of experimental acute destructive pancreatitis (ADP) in rats by assessing mortality, hematological, biochemical and serological parameters.
Material and methods. The experiment was carried out on 4 groups of rats, 18 individuals in each. ADP was modeled by injecting a 10% sodium dodecyl sulfate solution into the pancreatic tissue. After ADP modeling in group No.1 no treatment was performed, in group No.2 standard treatment was carried out for 3 days, in group No.3 against the background of standard treatment, tocilizumab was used once at a dose of 4 mg/kg, in group No.4 – standard treatment using tocilizumab at a dose of 8 mg/kg. Following this, laboratory tests were performed on the control day. The obtained data were subjected to comparative statistical analysis between the study groups. Mortality rates, laboratory inflammatory markers, and laboratory changes in target organs were assessed.
Results. In groups No.1 and No.2, mortality is 16.67% and 22.22%, respectively. In groups No.3 and No.4, where tocilizumab was used, mortality made up 0%. Also in groups No.3 and No.4 there is a statistically significant decrease in laboratory parameters (white blood cells count, stab and segmental neutrophils, interleukin-6, creatinine, alanine aminotransferase, aspartate aminotransferase, alpha-amylase, C-reactive protein) relative to groups No.1 and No.2. Moreover, in group No.4, using tocilizumab at a dosage of 8 mg/kg, white blood cells count, segmental and stab neutrophils, and creatinine level were significantly lower than those in group No.3, where a dose of 4 mg/kg was used.
Conclusions. The use of tocilizumab in ADP in the experiment ensures not only the absence of mortality, but a decrease in laboratory parameters (white blood cells count, stab and segmental neutrophils, interleukin-6, creatinine, alanine aminotransferase, aspartate aminotransferase, alpha-amylase, C-reactive protein). Moreover, the use of the drug at a dosage of 8 mg/kg turned out to be more effective than at a dose of 4 mg/kg due to a further reduction in hematological (white blood cells count, segmental and stab neutrophils) and biochemical (creatinine level) parameters.
Keywords: acute destructive pancreatitis, interleukin-6, interleukin-6 inhibitor, experiment, treatment of pancreatitis, laboratory data.
Acknowledgments. The author expresses his sincere gratitude to the reviewers of the article.
References
1. Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019 Jan;156(1):254-272.e11. doi: http://dx.doi.org/10.1053/j.gastro.2018.08.063
2. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006 May;354(20):2142-50. doi: http://dx.doi.org/10.1056/NEJMcp054958
3. Koshevskiy PP, Alekseev SA, Popkov OV, Ginyuk VA, Bovtyuk NYa. Pancreatogenic morphostructural changes in heart, lungs and other target organs in destructive pancreatitis. Neotlozh Kardiologiya Kardiovaskulyar Riski. 2021;5(1):1217-22. (In Russ.). doi: http://dx.doi.org/10.51922/2616633X.2021.5.2.1217
4. Pezzilli R, Bellacosa L, Felicani C. Lung injury in acute pancreatitis. JOP. 2009 Sep;10(5):481-4.
5. Watanabe T, Kudo M, Strober W. Immunopathogenesis of pancreatitis. Mucosal Immunol. 2017 Mar;10(2):283-298. doi: http://dx.doi.org/10.1038/mi.2016.101
6. Sternby H, Hartman H, Thorlacius H, Regnér S. The Initial Course of IL1β, IL-6, IL-8, IL-10, IL-12, IFN-γ and TNF-α with Regard to Severity Grade in Acute Pancreatitis. Biomolecules. 2021 Apr 17;11(4):591. doi: http://dx.doi.org/10.3390/biom11040591
7. Drutskaya MS, Nosenko MA, Atretkhany KSN, Efimov GA, Nedospasov SA. Interleukin-6 - from molecular mechanisms of signal transduction to physiologic functions and therapeutic targets. Molekulyar Biologiya. 2015;49(6):937. (In Rus.). doi: http://dx.doi.org/10.7868/S0026898415060063
8. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014 Sep;6(10):a016295. doi: http://dx.doi.org/10.1101/cshperspect.a016295
9. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990 Dec ;63(6):1149-57. doi: http://dx.doi.org/10.1016/0092-8674(90)90411-7
10. Su H, Lei CT, Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol. 2017 Apr:8:405. doi: http://dx.doi.org/10.3389/fimmu.2017.00405
11. Saad MI, Weng T, Lundy J, Gearing LJ, West AC, Harpur CM, et al. Blockade of the protease ADAM17 ameliorates experimental pancreatitis. Proc Natl Acad Sci U S A. 2022 Oct;119(42):e2213744119. doi: http://dx.doi.org/10.1073/pnas.2213744119
12. Zhang H, Neuhöfer P, Song L, Rabe B, Lesina M, Kurkowski MU, et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest. 2013 Mar;123(3):1019-31. doi: http://dx.doi.org/10.1172/JCI64931
13. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014 Feb;26(1):2-12. doi: http://dx.doi.org/10.1016/j.smim.2013.11.002
14. Viedma JA, Pérez-Mateo M, Domínguez JE, Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut. 1992 Sep;33(9):1264-7. doi: http://dx.doi.org/10.1136/gut.33.9.1264
15. Samgina TA, Zhivotova GA, Nazarenko PM, Polonikov AV. Role of cytokine gene polymorphisms in the development of acute pancreatitis: analysis of intergenic and gene-mediated interactions. Ros Zhurn Gastroenterologii Gepatologii Koloproktologii. 2017;27(3):27-33. (In Russ.). doi: http://dx.doi.org/10.22416/1382-4376-2017-27-3-27-33
16. Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC, Papachristou GI. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. Pancreatology. 2009;9(6):777-85. doi: http://dx.doi.org/10.1159/000214191
17. Stimac D, Fisić E, Milić S, Bilić-Zulle L, Perić R. Prognostic values of IL-6, IL-8, and IL-10 in acute pancreatitis. J Clin Gastroenterol. 2006 Mar;40(3):209-12. doi: http://dx.doi.org/10.1097/00004836-200603000-00007
18. Xu F, Hu X, Li SL. Value of serum CRP and IL-6 Assays combined with Pancreatitis activity scoring system for assessing the severity of patients with acute pancreatitis. Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):145-9. doi: http://dx.doi.org/10.12669/pjms.40.1.7550
19. Hashizume M, Tan SL, Takano J, Ohsawa K, Hasada I, Hanasaki A, et al. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. Int Rev Immunol. 2015 May;34(3):265-79. doi: http://dx.doi.org/10.3109/08830185.2014.938325
20. Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023 Jun;22(6):449-75. doi: http://dx.doi.org/10.1038/s41573-023-00672-y
21. Gulyants ES, Lukash NA, Tkacheva TN, Surgutanova TA, Kalmykova YuA; zayavitel' i patentoobladatel' Rostov med in-t. A method for modeling pancreatitis: pat 1327152 SSSR: MPK G 09 B 23/28. № 4026653/28-14; zayavl 17.02.86; opubl 30.07.87, Бюл № 28. 3 p. (In Russ.)
Submitted 09.07.2024
Accepted 28.08.2024
Information about authors:
A.I. Masyukevich – lecturer of the Chair of General Surgery, Grodno State Medical University, https://orcid.org/0000-0003-3514-9000,
e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. –Alexey I. Masyukevich.
